DDInter1174 DDInter1376
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methotrexate {u} (Compound) resembles {v} (Compound) Raltitrexed
Methotrexate {u} (Compound) resembles {v} (Compound) Tetrahydrofolic acid
Methotrexate {u} (Compound) treats {v} (Disease) stomach cancer
Methotrexate {u} (Compound) binds {v} (Gene) SLC16A1
Methotrexate {u} (Compound) upregulates {v} (Gene) PDLIM1
Methotrexate {u} (Compound) is included by {v} (Pharmacologic Class) Folic Acid Metabolism Inhibitors
Methotrexate {u} (Compound) downregulates {v} (Gene) TMEM50A
Methotrexate {u} (Compound) causes {v} (Side Effect) Ecchymosis
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Haloperidol
Methotrexate (Compound) resembles Raltitrexed (Compound)
Methotrexate (Compound) resembles Tetrahydrofolic acid (Compound)
Methotrexate (Compound) treats stomach cancer (Disease)
Methotrexate (Compound) binds SLC16A1 (Gene)
Methotrexate (Compound) upregulates PDLIM1 (Gene)
Methotrexate (Compound) is included by Folic Acid Metabolism Inhibitors (Pharmacologic Class)
Methotrexate (Compound) downregulates TMEM50A (Gene)
Methotrexate (Compound) causes Ecchymosis (Side Effect)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Haloperidol